A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is application/pdf.
571 Penpulimab for relapsed/refractory (R/R) classical hodgkin's lymphoma (cHL): Extended follow-up of the multicenter, single-arm, phase 2 study
2022
Regular and Young Investigator Award Abstracts
unpublished
Preserved Fulltext
Table 1 Efficacy data evaluated by IRC based on 2014 Lugano classification in the full analysis set (FAS; n=85)
doi:10.1136/jitc-2022-sitc2022.0571
fatcat:yvzozo46gfd6zjwq5o72m53vhu